Pay in 4 interest-free payments of $6.00 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
Future GLP-1 trends: new drugs and therapies on the horizon The future of weight management may soon involve more than current GLP-1s: Amylin mimetics: These compounds mimic another satiety hormone and may complement GLP-1s. Mazdutide: A dual glucagon/GLP-1 agonist showing strong Phase 3 results and promising greater weight loss. Oral GLP-1s: Pills in development could improve convenience. Muscle-preserving combinations: Researchers are exploring co-therapies to prevent loss of lean mass during weight loss. Providers should prepare for a rapidly evolving landscape and educate patients about upcoming options. Key takeaways on GLP-1 trends for providers and patients Efficacy varies across drugs and doses
If any answer is no, discuss adjustments with your provider
Morgan Healthcare Conference in January 2026, AbbVies Chief Medical Officer, Roopal Thakkar, explicitly stated, We have the longer-acting amylin
FAQ What does the research on AOD-9604 show
US$ 20.96
US$ 28.60
US$ 25.65
US$ 20.94
US$ 22.97
